First Trade Date for Genzyme Corp.
| Company Name | First Trade Date (yyyy-mm-dd) |
| Genzyme Corp. | unsure |
| Company Name | Symbol |
| Genzyme Corp. | GENZ |
| History and Business of Company (this information may include date of incorporation) | |
|
Genzyme Corp. develops and markets therapeutic, surgical and diagnostic products and genetic diagnostic services; develops, makes and markets biological products for the treatment of cartilage damage and severe burns; and develops cancer products. A highly diversified company, Genzyme Corp. uses a wide range of technologies to provide human health care products and services. Genzyme is comprised of three divisions, Genzyme General, Genzyme Tissue Repair and Genzyme Molecular Oncology, each of which has its own common stock intended to reflect its value and track its performance. Genzyme General develops and markets therapeutic and surgical products and diagnostic services and products. Genzyme Tissue Repair is a leading developer of biological products and devices for orthopedic injuries and severe burns. Genzyme Molecular Oncology (formed in connection with the June 1997 acquisition of PharmaGenics Inc.) develops cancer products, with a focus on therapeutic vaccines and angiogenesis inhibitors. The company says that treatment with Genzyme General's Cerezyme enzyme or Ceredase enzyme replacement therapy represents the only safe and effective treatment for Type I Gaucher disease, a seriously debilitating, sometimes fatal, genetic disorder caused by a deficiency in an important enzyme in the body called glucocerebrosidase. In late 1998, the FDA granted marketing approval for Renagel Capsules for the reduction of serum phosphorous in patients with end-stage renal disease, and for Thyrogen hormone for use as an adjunctive tool in follow-up screening of patients who have been treated for thyroid cancer. The company also produces synthetic phospholipids, is a commercial-scale contract manufacturer of synthetic peptides, and is developing the recombinant enzyme alpha-L-iduronidase, a recombinant form of the human enzyme alpha-galactosidase as a treatment for Fabry disease, transgenically produced alpha- glucosidase for the treatment of Pompe disease, and other products. Genzyme General's surgical products business consists mainly of three product lines: cardiovascular surgery, general surgery and plastic surgery. The company markets its surgical products directly to cardiac, general, colon and rectal surgeons and hospital purchasing departments throughout the U.S. and Europe. Genzyme General also provides three types of genetic diagnostic services (biochemical testing, classical and molecular cytogenetic testing and DNA testing), and it is a primary supplier of diagnostic components, bulk reagents and devices to makers of clinical diagnostic reagents and kits and to clinical reference laboratories. Genzyme Tissue Repair's focus is on orthopedics and burn care. Its lead product, Carticel, is used to treat damaged articular knee cartilage. Genzyme Tissue Repair's Epicel skin grafts - cultured autologous skin cells used as permanent skin replacement for patients with severe burns - are marketed to burn centers in the U.S. and overseas. Genzyme Molecular Oncology is developing a new generation of cancer products with an emphasis on cancer vaccines and angiogenesis inhibitors. Its products and services include a genomics service business based on its patented Serial Analysis of Gene Expression, or SAGE, technology; and therapeutic product candidates in various stages of development, including gene immunotherapies, angiogenesis inhibitors and cancer pathway regulators. INCORPORATED in Mass. in Nov., 1991, as Genzyme Massachusetts Corp.; present title adopted upon merger Dec. 31, 1991, of Genzyme Corp. (Predecessor), share-for-share. Predecessor was incorporated in Del. in June, 1981. OFFICE- One Kendall Square, Cambridge, MA 02139 (Tel.: 617-252-7500). FAX - 617-252-7600. WEBSITE- http://www.genzyme.com. | |
IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.
Back to first trade date main page
Back to financial astrology page
© 1999-2004 by Magi Astrologers Worldwide Corporation. All Rights Reserved.